SCHEMBL375198

SCHEMBL375198

CCOC(=O)c1ccc(=O)n(-c2c(Cl)cccc2Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
BAZ2B Q9UIF8 1/20 0.44
BAZ2A Q9UIF9 1/20 0.44
KDM4E B2RXH2 3/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
HPGD P15428 3/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HSP90AA1 P07900 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504671 0.86 CA12 (0.45) ALDH1A1MAPTLMNACA12CA1
SCHEMBL1504750 0.85 LMNA (0.49) ALDH1A1MAPTLMNAKDM4ECYP1A2
SCHEMBL11308735 0.79 ALDH1A1 (0.54) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL375794 0.78 ALDH1A1 (0.41) ALDH1A1MAPTKDM4ETDP1CYP1A2
SCHEMBL25078069 0.77 MAPT (0.50) ALDH1A1MAPTLMNAKDM4ECA12
SCHEMBL1504800 0.76 MAPK14 (0.47) ALDH1A1MAPTLMNAKDM4EL3MBTL1
SCHEMBL4252666 0.76 LMNA (0.53) ALDH1A1MAPTLMNAKDM4ECA12
SCHEMBL25078177 0.75 MAPT (0.47) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL25078486 0.75 HTT (0.43) ALDH1A1MAPTLMNACA12CA1
SCHEMBL25078446 0.75 LMNA (0.49) ALDH1A1MAPTLMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1810972-B1 NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO (JP) 2012-01-25 EP disclosed
US-7713998-B2 Nitrogenous heterocyclic compound and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-05-11 US disclosed
US-20070265308-A1 Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-15 US disclosed
EP-1810972-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265308-A1 Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof MAPK1, MAPK13, MAPK6 ALDH1A1 2069/4885MAPT 1039/4885LMNA 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.